The effect of human gene therapy for RPE65-associated Leber’s congenital amaurosis on visual function: a systematic review and meta-analysis

Table 2 Characteristics of included studies

Studies	Age^& (years)	Type of study	Number of eyes enrolled		Eye stratified by BCVA		Follow-up (months)	Outcome measures used	Quality score
Studies	Age^& (years)	Type of study	Treated	Untreated	Better BCVA*	Worse BCVA*	Follow-up (months)	Outcome measures used	Quality score
Jacobscon.et al. 2012 [12]	20	P	15	15	11/11	4/4	36	CRT, FST	7.5
Testa.et al. 2013 [13]	20	P	5	5	2/3	3/2	12–36	BCVA	6.5
Bainbridge.et al. 2015 [14]	14	P	12	12	11/11	1/1	12–36	BCVA, CRT	7.5
Weleber.et al. 2016 [15]	25	P	12	12	7/7	5/5	24	BCVA	7.5
Russell.et al. 2017 [16]	15	RCT	40^#	18^#	32^#/16^#	8^#/2^#	12	BCVA, CRT, FST	RCT
Le Meur.et al. 2018 [17]	24	P	9	9	5/7	4/2	12–36	BCVA	7.5

& - average age at recruitment (years)
# - bilateral administration
*Better BCVA - baseline BCVA better than 1.3 logMAR; *Worse BCVA - baseline BCVA worse than 1.3 logMAR
Legend: P – prospective clinical trial; RCT – randomized controlled clinical trial; BCVA - best-corrected visual acuity; CRT - central retinal thickness; FST - full-field sensitivity threshold

ISSN: 1750-1172